Targeted Gene Delivery for
Immune-Mediated Diseases
Today’s gene delivery technologies cannot precisely and efficiently deliver payloads to specific cell types in vivo—especially antigen-specific lymphocyte subsets. This limits the therapeutic potential of in vivo gene therapy.
We are developing an off-the-shelf, virus-like particle (VLP) platform engineered to precisely target defined lymphocyte subtypes with high efficiency and low immunogenicity. This enables potent, systemic, and antigen-specific in vivo delivery of gene therapies.
STAR Vectors: Solving Antigen-Specific Delivery
Our STAR Vectors are a new class of synthetic gene delivery vehicles that overcome the key limitations of viral and non-viral systems.
Platform
Precise targeting without compromising manufacturability
Modular surface engineering for rapid development of new targets and payloads
Off-the-shelf delivery system with no need for ex-vivo manipulation
Low immunogenicity
CMC leverages existing manufacturing infrastructure
Capable of delivering in vivo CAR-T therapies and non-integrating gene payloads
Therapeutic Focus Areas:
Autoimmune diseases: Targeting autoreactive T cells to reprogram immune responses
Oncology: Strengthening T-Cell responses in tumor-infiltrating lymphocytes
Chronic Viral Infection: Strengthening T-Cell responses in virus-targeting lymphocytes